- Home
- PFE
PFE
Pfizer Inc.
as of 03-24-2026 11:08am EST
$26.87
+$0.08
+0.30%
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
| Founded: | 1849 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 155.2B | IPO Year: | 2013 |
| Target Price: | $28.15 | AVG Volume (30 days): | 32.4M |
| Analyst Decision: | Hold | Number of Analysts: | 13 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 1.36 | EPS Growth: | -3.55 |
| 52 Week Low/High: | $20.91 - $27.94 | Next Earning Date: | 04-28-2026 |
| Revenue: | $62,579,000,000 | Revenue Growth: | -1.65% |
| Revenue Growth (this year): | -1.29% | Revenue Growth (next year): | -3.62% |
| P/E Ratio: | 19.82 | Index: | |
| Free Cash Flow: | 9.1B | FCF Growth: | -7.73% |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 3, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 3, 2026 · 100% conf.
AI Prediction SELL
1D
+0.23%
$25.84
Act: +4.46%
5D
-2.01%
$25.27
Act: +7.08%
20D
-3.05%
$25.00
Act: +3.12%
Price: $25.79 Prob +5D: 0% AUC: 1.000
0000078003-26-000005
pfe-202602030000078003false00000780032026-02-032026-02-030000078003us-gaap:CommonStockMember2026-02-032026-02-030000078003pfe:NotesDue20271.000Member2026-02-032026-02-030000078003pfe:NotesDue20292.875Member2026-02-032026-02-030000078003pfe:NotesDue20323.250Member2026-02-032026-02-030000078003pfe:NotesDue20373.875Member2026-02-032026-02-030000078003pfe:NotesDue20454.250Member2026-02-032026-02-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 3, 2026
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE/27 New York Stock Exchange 2.875% Notes due 2029
PFE/29
New York Stock Exchange 3.250% Notes due 2032
PFE/32
New York Stock Exchange 3.875% Notes due 2037
PFE/37A
New York Stock Exchange 4.250% Notes due 2045
PFE/45
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On February 3, 2026, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the fourth quarter of 2025. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated February 3, 2026, reporting Pfizer’s financial results for the fourth quarter of 2025.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
EXHIBIT INDEX
Exhibit No.Description
99 Press Release of Pfizer Inc. dated February 3, 2026, reporting Pfizer’s financial results for the fourth quarter of 2025.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PFIZER INC.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: February 3, 2026
2025 Q3 Q3 2025 Earnings
8-K Nov 4, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 4, 2025
0000078003-25-000149
pfe-202511040000078003false00000780032025-11-042025-11-040000078003us-gaap:CommonStockMember2025-11-042025-11-040000078003pfe:NotesDue20271.000Member2025-11-042025-11-040000078003pfe:NotesDue20292.875Member2025-11-042025-11-040000078003pfe:NotesDue20323.250Member2025-11-042025-11-040000078003pfe:NotesDue20373.875Member2025-11-042025-11-040000078003pfe:NotesDue20454.250Member2025-11-042025-11-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 4, 2025
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE/27 New York Stock Exchange 2.875% Notes due 2029
PFE/29
New York Stock Exchange 3.250% Notes due 2032
PFE/32
New York Stock Exchange 3.875% Notes due 2037
PFE/37A
New York Stock Exchange 4.250% Notes due 2045
PFE/45
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On November 4, 2025, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the third quarter of 2025. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated November 4, 2025, reporting Pfizer’s financial results for the third quarter of 2025.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
EXHIBIT INDEX
Exhibit No.Description
99 Press Release of Pfizer Inc. dated November 4, 2025, reporting Pfizer’s financial results for the third quarter of 2025.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PFIZER INC.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: November 4, 2025
2025 Q2 Q2 2025 Earnings
8-K Aug 5, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 5, 2025
0000078003-25-000136
pfe-202508050000078003false00000780032025-08-052025-08-050000078003us-gaap:CommonStockMember2025-08-052025-08-050000078003pfe:NotesDue20271.000Member2025-08-052025-08-050000078003pfe:NotesDue20292.875Member2025-08-052025-08-050000078003pfe:NotesDue20323.250Member2025-08-052025-08-050000078003pfe:NotesDue20373.875Member2025-08-052025-08-050000078003pfe:NotesDue20454.250Member2025-08-052025-08-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 5, 2025
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE/27New York Stock Exchange 2.875% Notes due 2029
PFE/29
New York Stock Exchange 3.250% Notes due 2032
PFE/32
New York Stock Exchange 3.875% Notes due 2037
PFE/37A
New York Stock Exchange 4.250% Notes due 2045
PFE/45
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On August 5, 2025, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the second quarter of 2025. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated August 5, 2025, reporting Pfizer’s financial results for the second quarter of 2025.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
EXHIBIT INDEX
Exhibit No.Description
99 Press Release of Pfizer Inc. dated August 5, 2025, reporting Pfizer’s financial results for the second quarter of 2025.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PFIZER INC.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: August 5, 2025
Latest Pfizer Inc. News
PFE Breaking Stock News: Dive into PFE Ticker-Specific Updates for Smart Investing
MT Newswires
Traders Digest Signs of Easing Middle East Tensions as US Equity Futures Rise Pre-Bell
➖
AI Sentiment
Neutral
5/10
TMX Newsfile
Telescope Innovations Announces Expansion of Consulting Role for Dr. Joel M. Hawkins, Industry Leader in Process Chemistry Automation
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Pfizer, Valneva Say Potential Lyme Disease Vaccine Reduces Infection by Over 73% in Phase 3 Study
➖
AI Sentiment
Neutral
5/10
The Wall Street Journal
Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial
📈
AI Sentiment
Highly Positive
8/10
Business Wire
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
📈
AI Sentiment
Highly Positive
9/10
StockStory
2 Unpopular Stocks That Should Get More Attention and 1 We Avoid
📉
AI Sentiment
Negative
3/10
Compare PFE vs Leading Stocks
See how PFE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PFE Pfizer Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.